Interleukin-18 (IL-18) is a cytokine which was identified based on its ability to induce production of gamma interferon (IFN-␥) by T cells and enhance natural killer (NK) cell cytolytic activity (23, 38) . IL-18 is structurally related to members of the IL-1 family (2) and is processed by IL-1 converting enzyme (ICE) (16, 17) . In addition, IL-18 uses an IL-1-like signaling pathway that leads to the activation of NF-B (31, 52) . Although IL-18 is a member of the IL-1 family, it is functionally similar to IL-12. Thus, like IL-12, IL-18 increases production of IFN-␥ by NK and T cells (23, 43, 56, 58, 59) , augments cytotoxic activity of NK and CD8
ϩ T cells (6, 18) , and enhances immunity to tumors and infection (3, 5, 30, 37) . Moreover, IL-18-deficient mice have impaired IFN-␥ responses following infection with intracellular pathogens (26, 51, 55) .
Innate resistance to toxoplasmosis is dependent on the ability of IL-12 to stimulate NK cell production of IFN-␥ (15, 22) . However, the development of optimal NK cell responses required for resistance to T. gondii is dependent on soluble and cell-bound ligands (CD28, IL-1, and TNF-␣) which enhance the IL-12-induced NK cell production of IFN-␥ (14, 20, 21, 25, 47) . Since NK cells constitutively express the IL-18 receptor (24) and IL-18 is a potent enhancer of NK cell activity and synergizes with IL-12 to stimulate NK cell production of IFN-␥ (23, 54, 59) , it is a likely candidate to be involved in the regulation of innate resistance to T. gondii. The studies presented here suggest that endogenous IL-18 has a minor role in resistance to T. gondii but demonstrate that exogenous IL-18 can enhance NK cell-mediated resistance to this pathogen.
MATERIALS AND METHODS

Antibodies and cytokines.
A two-site enzyme-linked immunosorbent assay (ELISA) was employed to assay levels of IFN-␥ as previously described (44) .
IL-18 levels were measured using a rat monoclonal antibody (MAb) specific for IL-18 as capture antibody and a polyclonal goat anti-IL-18 antibody (both antibodies were supplied by R&D Systems, Inc., Minneapolis, Minn.), in combination with a peroxidase-conjugated donkey anti-goat immunoglobulin G (IgG; Jackson Immunoresearch Laboratories, Inc., West Grove, Pa.) for detection. The sensitivity of this assay was routinely 39 pg of recombinant murine (rm) IL-18 per ml. The rabbit polyclonal anti-IL-18 used for in vivo neutralization studies was generated by multiple immunization of a rabbit with rmIL-18 provided by DNAX (5) . In vitro assays showed that 20 g of anti-IL-18 per ml could completely inhibit the production of IFN-␥ induced by 10 ng of IL-18 per ml (data not shown). IL-12p40 levels were measured using MAb C17.8 and biotinylated MAb C15.6 prepared from hybridomas provided by G. Trinchieri (Wistar Institute). rmIFN-␥ was purchased from Genzyme (Cambridge, Mass.). rmIL-18 was purchased from Pepro Tech, Inc. (Rocky Hill, N.J.). rmIL-12 was supplied by the Immunology Department of Genetics Institute (Cambridge, Mass.). Anti-asialoGM1 was purchased from Wako Chemicals, USA, Inc. (Richmond, Va.). Rabbit IgG and rat IgG were purchased from Sigma (St. Louis, Mo.).
Mice, infection, and cytokine treatment. SCID B/6 mice were bred and maintained in Thoren caging units within the animal facility in the Gene Therapy Animal Facility of the University of Pennsylvania or purchased from Jackson Laboratory (Bar Harbor, Maine) and were 6 to 8 weeks of age when used in the experiments. Mice were routinely infected intraperitoneally (i.p.) with 20 cysts of the ME-49 strain of T. gondii. CBA/ca mice were purchased from Jackson Laboratory and were used to maintain the ME-49 strain of T. gondii and as a source of cysts for infection. To assess parasite burden at the local site of infection, 3 ml of phosphate-buffered saline (PBS) were injected into the peritoneal cavity of infected mice; cells were collected, and cytospins were prepared and stained with Diff-Quik (Dade Diagnostics of P.R. Inc., Aguada, Puerto Rico), and the percentage of peritoneal exudate cells (PECs) infected was estimated by microscopy. The percentage of cells infected was estimated by counting Ͼ500 cells/cytospin. To determine the effects of exogenous IL-18 on resistance to T. gondii, SCID mice were given 200 ng of IL-18 i.p. 1 day before infection and daily thereafter.
In vivo depletion. To deplete NK cells, SCID mice were treated i.p. with 50 g of anti-asialoGM1 3 days before infection and every 3 days thereafter. Fluorescence-activated cell sorting (FACS) analysis showed at least 98% depletion of NK1.1 ϩ cells. Rabbit IgG was used to treat control mice. To assess the role of endogenous IL-18, SCID mice were treated with anti-IL-18 antibody or an isotype control at a dose of 2 mg/mouse on days Ϫ1, 1, and 3. For depletion of IL-12 or IFN-␥, SCID mice were given 0.75 mg of anti-IL-12 (C17.8) or 1 mg of anti-IFN-␥ MAb (XMG6) or isotype control antibodies i.p. on days Ϫ1 and 3.
Analysis of IFN-␥ production by NK cells. Splenocytes from SCID mice were prepared as previously described (22) . Briefly, spleens were dissociated in complete RPMI (10% heat-inactivated fetal calf serum, 2 mM glutamine, 1,000 U of penicillin per ml, 10 g of streptomycin per ml, 0. Nitric oxide (NO) assay. PECs were harvested and plated out at 10 5 /well in a final volume of 200 ml per well. The cells were cultured in the medium alone for 24 h, and the levels of NO were measured using the Greiss assay. Briefly, 100 l of the samples (supernatant) or the standard (NaNO 2 ) was mixed with 100 l of solution C, which was prepared by mixing an equal volume of solution A (sulfanilamide [1%] in 2.5% H 3 PO 4 [phosphoric acid]) and solution B (napthylethylenediamine dihydrochloride [0.1%] in 2.5% H 3 PO 4 ). The reaction was developed for 10 min at room temperature before reading it at 562 nm on an enzyme-linked immunosorbent assay (ELISA) plate reader.
Cytotoxicity assay. Cytotoxicity assays were performed as previously described (53) . Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 Ci of 51 Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51 Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.
Immunohistochemistry. For histological analysis of tissues from infected mice, samples of livers, lungs, and spleens were removed from each mouse and fixed overnight in Accustain 10% Formalin neutral buffered solution (Sigma Diagnostics, St. Louis, Mo.) and then embedded in paraffin. Next, 5-m paraffin sections were incubated for 1 h at 60°C and then rehydrated. Sections were incubated for 30 min with 0.3% H 2 O 2 -0.2 M NaN 3 to quench endogenous peroxidase activity, followed by blocking with 10% goat serum (Vector Laboratories, Burlingame, Calif.) in Hanks balanced salt solution (HBSS). Sections were then incubated for 1 h at room temperature with primary rabbit antibody against iNOS (Transduction Laboratories, Lexington, Ky.) or T. gondii (from Fausto, G. Araujo, Palo Alto Medical Foundation) or an isotype control antibody (Sigma). After being washed in HBSS, sections were incubated with biotinylated anti-rabbit IgG antibody (Vector Laboratories). To visualize specific staining, sections were incubated with a peroxidase-conjugated avidin-biotin complex (Vectastain Elite ABC kit; Vector) according to the manufacturer's instructions, followed by incubation with 3,3Ј-diaminobenzidine (Vector), and counterstained with hematoxylin, dehydrated, and mounted in Permount (Fisher Scientific, Fair Lawn, N.J.).
FACS analysis. The phycoerythrin (PE)-labeled anti-NK1.1 MAb was purchased from Pharmingen. For FACS analysis of NK cells, cells were incubated with purified anti-mouse CD32/CD16 to block nonspecific binding of MAbs to Fc receptors, followed by incubation with a PE-labeled anti-NK1.1 MAb for 30 min at 4°C. Background fluorescence was assessed using an irrelevant isotype control MAb (Pharmingen). Stained cells were analyzed with a FACScan cytoflurometer (Becton Dickinson Co., Mountain View, Calif.).
RNase protection assay (RPA). Total RNA was extracted from spleens using Tri-Reagent (Sigma) and was assessed for cytokine mRNA content using the RiboQuant MultiProbe RNase Protection Assay System (Pharmingen). Briefly, 10 g of RNA from each sample was hybridized in solution with the radiolabeled mCK-2b (containing IL-12p35, IL-12p40, IL-10, IL-1␣, IL-1␤, IL-1Ra, IL-18, IL-6, and IFN-␥) antisense RNA probe. Following hybridization, free probe and remaining single-stranded RNA were digested with RNase, and the protected probes were purified and resolved on 5% denaturing polyacrylamide gels using UltraPure Sequagel reagents (National Diagnostics, Atlanta, Ga.). Dried gels were then exposed to phosphorimaging screens, and protected fragments were visualized using a phosphorimager (GS-525; Bio-Rad, Culver City, Calif.). The quantity of protected RNA was determined using MultiAnalyst software (BioRad) by measuring the density of each sample and subtracting the background levels. The relative expression of cytokine mRNA was determined by calculating the ratio of cytokine mRNA to housekeeping gene mRNA.
Statistics. Statistical analysis (unpaired Student's t test, Mann-Whitney) was performed using INSTAT software (GraphPad Software, San Diego, Calif.). A P value of Ͻ0.05 was considered significant.
RESULTS
Production of IL-18 during toxoplasmosis.
Previous studies have demonstrated that IL-18 is a proinflammatory cytokine which enhances production of IFN-␥ by NK and T cells and is upregulated in response to infection (33, 41, 42) . To determine if infection with T. gondii results in increased expression of IL-18, SCID mice were infected with T. gondii, and the levels of IL-18 mRNA in the spleen and IL-18 protein in the serum on day 7 postinfection were assessed. RPA analysis showed that, whereas levels of IL-12 and IFN-␥ mRNA in the spleen were upregulated following infection, there were constitutive levels of mRNA for IL-18 in uninfected mice, and these were not significantly altered following infection (Fig. 1A and B) . However, increased levels of IL-18 were detected in the serum of SCID mice following infection (Fig. 1C) , and similar results were also observed by day 3 postinfection (data not shown). These data demonstrate that infection with T. gondii does result in increased serum levels of IL-18 mRNA but not of IL-18 mRNA. These data are consistent with a posttranslational mechanism to regulate secretion of IL-18 (16, 17) .
Role of endogenous IL-18 in resistance to T. gondii. To explore the role of endogenous IL-18 in innate resistance to T. gondii, SCID mice were treated with a neutralizing rabbit polyclonal antibody specific for IL-18. Administration of anti-IL-18 to infected mice abrogated the infection-induced increase in serum levels of IL-18 on all days tested (days 3, 5, 7, and 10 [data not shown]) and resulted in a decrease in serum IFN-␥ levels on day 3 postinfection (Fig. 2A) . However, by days 7 and 10 postinfection, there was no significant difference in the serum levels of IFN-␥ between experimental groups. Moreover, treatment with anti-IL-18 had no effect on parasite burden on either day 5 or day 10 postinfection (Fig. 2B) or on the infection induced increase in NK cell cytotoxicity on day 5 postinfection (Fig. 2C) . In addition, treatment with anti-IL-18 did not alter the numbers of PECs recovered (isotype control ϭ 4.3 ϫ 10 6 Ϯ 1.2 ϫ 10 6 ; anti-IL-18 ϭ 5.3 ϫ 10 6 Ϯ 2.1 ϫ 10 6 ) or the total numbers of splenocytes (isotype control ϭ 7.6 ϫ 10 6 Ϯ 1.3 ϫ 10 6 ; anti-IL-18 ϭ 8.2 ϫ 10 6 Ϯ 2.2 ϫ 10 6 ) from mice infected for 5 days. The data presented are the means Ϯ the standard deviations derived from an experiment representative of three experiments performed with three mice per group. Consistent with these results, administration of anti-IL-18 in a single experiment had no effect on the time to death of SCID mice infected with T. gondii (data not shown).
In vitro analysis revealed that splenocytes from infected SCID mice stimulated with TLA produced low levels of IFN-␥, and this was enhanced by the addition of IL-18 or IL-12 (Fig. 3) . Moreover, the addition of IL-12 plus IL-18 in the presence of TLA resulted in at least two-to threefold-higher levels of IFN-␥ compared to either cytokine alone (data not shown). The production of IFN-␥ in these cultures was suppressed by the addition of anti-IL-12, and the ability of exogenous IL-18 to enhance production of IFN-␥ was reduced by more than 70% when anti-IL-12 was added (Fig. 3) . Furthermore, whereas IL-12p40 was readily detectable in cultures stimulated with TLA (ca. 10 ng/ml), IL-18 was not detected. Consistent with these latter results, the addition of anti-IL-18 did not significantly affect the ability of TLA alone or in combination with IL-12 to stimulate the production of IFN-␥ (data not shown). These results indicate that the ability of IL-18 to enhance production of IFN-␥ in this experimental system is largely dependent on endogenous IL-12. Together with the in vivo studies, these data suggest that endogenous IL-18 has a minor role in regulating the production of IFN-␥ required for innate immunity to T. gondii.
Administration of IL-18 enhances innate resistance to T. gondii. Since in vitro studies showed that IL-18 could enhance the parasite-induced production of IFN-␥ by splenocytes, IL-18 was administered to SCID mice to determine if this treatment could enhance resistance to T. gondii. Administration of IL-18 to SCID mice 1 day before infection and daily thereafter resulted in a significant decrease in parasite burden on days 10 and 16 postinfection (Fig. 4A ) and a 5-to 6-day delay in time to death (Fig. 4B) to 5 ϫ 10 6 , respectively. Immunohistochemical analysis of spleens from infected mice revealed that administration of IL-18 to SCID mice resulted in enhanced expression of iNOS associated with a decreased parasite burden (Fig. 4) . Similar results were observed at the local site of infection. Thus, PECs isolated from infected mice treated with IL-18 for 7 days and incubated in medium alone for 24 h produced 38.3 Ϯ 11.3 M of nitrite, whereas PECs from control infected mice produced Ͻ0.1 M (n ϭ 3 mice per group). In addition, analysis of the number of cysts in the brains of mice on day 16 postinfection revealed that IL-18 treatment resulted in no detectable cysts (n ϭ 3), while control mice treated with PBS had a mean of 4,166 Ϯ 650 cysts (n ϭ 3).
Administration of IL-18 to SCID mice resulted in a significant increase in serum levels of IFN-␥ on days 5 and 16 postin- fection (Fig. 5 ) but did not alter the infection-induced increase in serum levels of IL-12 (data not shown). FACS analysis revealed that administration of IL-18 to infected mice resulted in an increased percentage of NK cells at the local site of infection on day 16 postinfection, but there was no change in the total number of NK cells at this site compared to infected controls ( Fig. 5C , P Ͻ 0.05). This increase in the percentage of NK cells was not seen in either the spleens of treated mice on day 16 postinfection or in the PECs and splenocytes from mice infected for 7 days which were treated with PBS or IL-18. However, both PECs (Fig. 5B) and splenocytes from IL-18-treated SCID mice had higher levels of NK cell cytolytic activity (using YAC-1 cells as target cells) compared to control SCID mice on day 16 postinfection.
To assess the basis for the protective effects of exogenous IL-18, the roles of IL-12, IFN-␥, and NK cells in treated mice were analyzed. Depletion of IL-12 resulted in reduced serum levels of IFN-␥ in both IL-18-and PBS-treated mice (Fig. 6A) . In addition, our results showed that in the absence of IL-12, both IL-18-and PBS-treated SCID mice showed an increase in the percentage of infected PECs compared to isotype control mice on day 7 postinfection (Fig. 6B) . The total numbers of PECs recovered from mice treated with PBS plus isotype, PBS plus anti-IL-12, IL-18 plus isotype, and IL-18 plus anti-IL-12 on day 7 postinfection were 2.7 ϫ 10 6 Ϯ 2.4 ϫ 10 6 , 9.8 ϫ 10 6 Ϯ 3.1 ϫ 10 6 , 0.9 ϫ 10 6 Ϯ 0.7 ϫ 10 6 , and 1.8 ϫ 10 6 Ϯ 0.4 ϫ 10 6 , respectively, whereas splenocytes from these four groups were 11.0 ϫ 10 6 Ϯ 1.8 ϫ 10 6 , 3.9 ϫ 10 6 Ϯ 1.8 ϫ 10 6 , 23.2 ϫ 10 6 Ϯ 4.5 ϫ 10 6 , and 4.5 ϫ 10 6 Ϯ 3.1 ϫ 10 6 , respectively. However, mice treated with IL-18 plus anti-IL-12 had fewer parasites than mice treated with anti-IL-12 alone (P Ͻ 0.05) (Fig. 6B) . This reduction in parasite numbers correlated with a 2-to 3-day delay in time to death (P ϭ 0.0025) (Fig. 6C) . These results suggest that, although the protective effects of exogenous IL-18 are largely dependent on endogenous IL-12, there is an IL-18-dependent, IL-12-independent pathway that can enhance resistance to T. gondii.
Depletion of NK cells in SCID mice treated with IL-18 antagonized the delay in time to death seen in these mice (Fig.  7A) . NK cells are thought to be the major source of IFN-␥ in SCID mice and, in our studies, depletion of NK cells led to Ͼ90% reduction in serum levels of IFN-␥ during infection. However, low levels of IFN-␥ were detected in NK-depleted, IL-18-treated SCID mice, suggesting either incomplete depletion of NK cells or that there are alternative sources of IFN-␥ in SCID mice (12, 34, 57) . Nevertheless, depletion of IFN-␥ completely inhibited the protective effects of IL-18 (Fig. 7B) , and mice died by day 9 postinfection (data not shown). On day 7 postinfection, the total numbers of PECs recovered from mice treated with PBS plus isotype, IL-18 plus isotype, PBS plus anti-IFN-␥ and IL-18 plus anti-IFN-␥ were 0.9 ϫ 10 6 , 1.3 ϫ 10 6 Ϯ 1.2 ϫ 10 6 , 11.6 ϫ 10 6 Ϯ 2.9 ϫ 10 6 , and 4.4 ϫ 10 6 Ϯ 2.5 ϫ 10 6 , respectively, and the total numbers of splenocytes of these four groups were 10 ϫ 10 6 Ϯ 0, 30 ϫ 10 6 Ϯ 10 ϫ 10 6 , 7.6 ϫ 
DISCUSSION
Previous studies have shown that infection with T. gondii results in increased production of IL-12 that is necessary for NK cell production of IFN-␥ required for innate resistance to this pathogen (13, 49, 50) . The data presented here demonstrate that, although infection resulted in an increase in serum levels of IL-18, these levels were low compared to other situations in which IL-18 has been shown to have a functional role (17) . Accordingly, depletion of endogenous IL-18 during toxoplasmosis resulted in only a transient reduction in levels of IFN-␥ and did not significantly affect parasite burden or survival. Thus, despite its functional similarity to IL-12, upregulation of IL-18 following infection appears to have a minor role in innate resistance to T. gondii. In support of this conclusion, mice deficient in the ICE (which is involved in the processing and secretion of IL-18) infected with T. gondii also have an early defect in their ability to produce IFN-␥ but are resistant to toxoplasmosis (G. Cai and C. A. Hunter, manuscript in preparation). Together, these studies suggest a limited role for endogenous IL-18 in T-cell-independent resistance to T. gondii. Nevertheless, future studies using IL-18 Ϫ/Ϫ mice will be necessary to confirm our findings on the role of endogenous IL-18 in resistance to toxoplasmosis. Consistent with our findings, other researchers have demonstrated that, during infection with Salmonella enterica serovar Typhimurium, endogenous IL-18 has a minor role in the production of IFN-␥ required for clearance of this intracellular pathogen (8, 9) . Interestingly, T. gondii and serovar Typhimurium induce high levels of nitric oxide during the acute stage of infection, and studies by Kim et al. demonstrated that nitric oxide can inhibit the production of IL-18 (28) , which may explain the low levels of IL-18 detected following infection with these pathogens. This may be a common mechanism to limit potentially pathogenic immune responses or a strategy for intracellular pathogens to inhibit protective immune responses.
Although endogenous IL-18 does not appear to be critical for innate resistance to T. gondii, administration of IL-18 to SCID mice did result in a significant reduction in the parasite burden associated with enhanced production of IFN-␥. In vivo depletion studies revealed that the protective effects of IL-18 were dependent on IL-12, IFN-␥, and NK cells, suggesting that the ability of IL-18 to synergize with IL-12 to stimulate NK cell production of IFN-␥ is the basis for the protective effects of exogenous IL-18. In support of this, the administration of IL-18 to uninfected SCID mice, in which there are low levels of endogenous IL-12, did not increase the total number of splenocytes or the NK cell activity or serum IFN-␥ levels compared to PBS-treated control mice. In contrast, the administration of IL-18 to infected SCID mice led to an increased percentage of NK cells in the peritoneal cavity, suggesting that IL-18 may enhance the recruitment of NK cells to the local sites. This may be due to the ability of IL-18 to stimulate chemokine production (11) or its ability to upregulate adhesion molecule expression (29) . However, these data have to be interpreted with care since many of the treatments used in these studies resulted in large changes in numbers of cells in the peritoneum and spleen. For example, administration of IL-18 to infected mice resulted in a twofold increase in the numbers of spleen cells, but a similar change was not observed at the local site of infection; rather, infected mice treated with IL-18 had sevenfold fewer PECs compared to untreated mice. One interpretation of these data is that these changes may be a function of the immune regulatory effects of exogenous IL-18 and a function of parasite burden. Thus, the immune effects of IL-18 may account for the increase in the numbers of cells in the spleen. In contrast, the lower numbers of inflammatory cells in the peritoneum are likely a reflection of the reduced parasite burden in mice treated with IL-18. This balance between immune regulatory effects and parasite burden could also explain why treatment with anti-IL-12 inhibited expansion of immune populations in the spleen but the 5-to 10-fold increase in parasite numbers in the peritoneum led to a 3-fold increase in the numbers of inflammatory cells at this site. Nevertheless, SCID mice treated with IL-18 still succumbed to toxoplasmosis within 4 weeks, and immunohistochemical analysis revealed that these mice could not control parasite growth in peripheral tissues (lungs, hearts, and brains) but did control parasite replication at the local site of infection and treatment (peritoneal cavity). This contrasts with untreated SCID mice that had large numbers of parasites in the peritoneum at the time they succumb to the infection on day 20. Why IL-18 can protect at the local site of treatment but not in other organs may be explained by the ultimate requirement for T cells for long-term resistance to T. gondii or a restricted ability of IL-18 activated NK cells to traffic to, and mediate protection at, different sites.
There are several reports of an IL-12-independent pathway that allows the generation of IFN-␥-dependent resistance to T. gondii (10, 45) , as well as to other intracellular pathogens (27, 40) . Our studies suggest that IL-18 can decrease parasite burden and delay time to death of SCID mice treated with anti-IL-12. This IL-12-independent protective effect is likely to be due to the ability of IL-18 alone to stimulate NK cells to produce low levels of IFN-␥ (4, 38). Thus, although serum levels of IFN-␥ were greatly reduced in mice treated with anti-IL-12, administration of IL-18 to these mice did enhance levels of IFN-␥ mRNA in the spleen (data not shown). Furthermore, mice deficient in the transcription factor STAT4 (required for IL-12-mediated signaling) are highly susceptible to toxoplasmosis; administration of IL-18 results in a reduced parasite burden but ultimately fails to protect these mice (G. Cai and C. A. Hunter, submitted for publication). Together, these studies suggest that exogenous IL-18 is a potent enhancer of IL-12-mediated resistance to T. gondii and, although it can enhance resistance to toxoplasmosis independently of IL-12, this is a relatively minor effect.
Recent studies have demonstrated the importance of endogenous IL-18 for enhancing the production of IFN-␥ following infection with Leishmania major, Staphylococcus aureus (55) , Mycobacterium tuberculosis (48) , and murine cytomegalovirus infection (26) . However, it appears that endogenous IL-18 is not required for innate resistance to T. gondii (this study) or serovar Typhimurium (9) . Thus, although IL-12 and IFN-␥ are central mediators of resistance to many of these pathogens (1, 7, 19, 46) , the requirement for IL-18 varies between pathogens. In addition, our studies demonstrate that the ability of IL-18 to mediate resistance to T. gondii is largely dependent on endogenous IL-12. Since it has been proposed that IL-18 may be useful for the treatment of infectious diseases (36) and cancer (5, 32, 35, 39) , the studies presented here add to our knowledge of the interactions between IL-12 and IL-18 necessary for optimal innate responses.
